In the cohort of 14 evaluable patients with B-ALL, response assessment on day 28 following the first infusion of CD19 CAR T cells showed an ORR of 78.6% (11/14; 95% CI: 49.2%–95.3%). Here, CD19 is linked to acute lymphoblastic leukemia.